{"id":150261,"date":"2010-01-07T12:27:19","date_gmt":"2010-01-07T17:27:19","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/01\/07\/the-latest-deal-in-the-big-pharma-generics-wars\/"},"modified":"2010-01-07T12:27:19","modified_gmt":"2010-01-07T17:27:19","slug":"the-latest-deal-in-the-big-pharma-generics-wars","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/150261","title":{"rendered":"The Latest Deal in the Big Pharma-Generics Wars"},"content":{"rendered":"

\"nexium\"The latest peace pact in the generics wars has been signed by AstraZeneca and Teva, shielding AstraZeneca’s mega-selling heartburn drug Nexium from Teva competition until 2014. Now the question is whether a similar deal with another generic maker — Dr. Reddy’s Laboratories — is far behind.<\/p>\n

AstraZeneca said<\/a> the deal will allow Teva to sell generic copies of Nexium in the U.S. starting on May 27, 2014, when the first of AstraZeneca’s patents on the drug expire. Back in 2008, AstraZeneca made a separate Nexium deal with India’s Ranbaxy Laboratories<\/a>.<\/p>\n

Morgan Stanley analysts quoted by Reuters<\/a> said that India’s Dr. Reddy’s posed the only credible risk to Nexium sales before 2014; they predicted AstraZeneca would cut a deal with Dr. Reddy’s before the end of 2010.<\/p>\n

All this fuss stems from the fact that Nexium is AstraZeneca’s biggest seller, ranking as the world’s third-largest drug, with sales of $7.8 billion, according to IMS Health<\/a>.<\/p>\n

Other drug makers have been cutting similar deals on mega-blockbusters losing patent protection in the coming years. Pfizer and Ranbaxy settled<\/a> their legal fight over Lipitor when they agreed that Ranbaxy could start selling generic copies of the drug (the biggest seller of all time) in November of 2011.<\/p>\n

Photo: PR Newswire<\/em><\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The latest peace pact in the generics wars has been signed by AstraZeneca and Teva, shielding AstraZeneca’s mega-selling heartburn drug Nexium from Teva competition until 2014. Now the question is whether a similar deal with another generic maker — Dr. Reddy’s Laboratories — is far behind. AstraZeneca said the deal will allow Teva to sell […]<\/p>\n","protected":false},"author":792,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-150261","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/150261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/792"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=150261"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/150261\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=150261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=150261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=150261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}